Effects of the cognition impairer MK-801 on learning and memory in mice and rats

Behavioural Brain Research

Volumn 220, Issue 1, 2011, Pages 215-229

  van der Staay, F Josef ^a,b   Rutten, Kris ^c   Erb, Christina ^d   Blokland, Arjan ^e  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c GRÜNENTHAL GMBH   (Germany)

^d BIOTEST AG   (Germany)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Animal model; Morris task; Object recognition; Passive avoidance; Social recognition; T maze alternation

Indexed keywords

DIZOCILPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; EXPERIMENTAL MODEL; LEARNING DISORDER; MAZE TEST; MEMORY CONSOLIDATION; MEMORY DISORDER; MOUSE; NEUROTOXICITY; NONHUMAN; OBJECT RELATION; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RECOGNITION; SHOCK; SOCIAL BEHAVIOR; SPATIAL MEMORY; TASK PERFORMANCE;

ANALYSIS OF VARIANCE; ANIMALS; ATTENTION; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; RATS; RATS, WISTAR; RECOGNITION (PSYCHOLOGY); SENSORY THRESHOLDS;

EID: 79952101514     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.01.052     Document Type: Article

References (109)

1. van der Staay F.J. Animal models of behavioral dysfunctions: basic concepts and classifications, and an evaluation strategy. Brain Res Rev 2006, 52:131-159.
2. Bartus R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000, 163:495-529.
3. Klinkenberg I., Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev 2010, 34:1307-1350.
4. Rutten K., Lieben C., Smits L., Blokland A. The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion. Psychopharmacology 2007, 192:275-282.
5. Van Donkelaar E., Rutten K., Blokland A., Akkermans S., Steinbusch H., Prickaerts J. Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan depletion. Eur J Pharmacol 2008, 600:98-104.
6. Riedel G., Platt B., Micheau J. Glutamate receptor function in learning and memory. Behav Brain Res 2003, 140:1-47.
7. Daw N.W., Stein P.S.G., Fox K. The role of NMDA receptors in information processing. Annu Rev Neurosci 1993, 16:207-222.
8. Danysz W., Zajaczkowski W., Parsons C.G. Modulation of learning processes by ionotropic glutamate receptor ligands. Pharmacol Biochem Behav 1996, 6:455-474.
9. Hölscher C. Synaptic plasticity and learning and memory: LTP and beyond. J Neurosci Res 1999, 58:62-75.
10. Milner B., Squire L.R., Kandel E.R. Cognitive neuroscience and the study of memory. Neuron 1998, 20:445-468.
11. Wong E.H.F., Kemp J.A., Priestley T., Knight A.R., Woodruff G.N., Iversen L.L. The anticonvulsant MK-801 is a potent N-methyl-d-aspartate antagonist. Proc Natl Acad Sci USA 1986, 83:7104-7108.
12. Ellison G. The N-methyl-d-aspartate antagonists phencylidine, ketamine and dizolcipine as both behavioral and anatomical models of dementia. Brain Res Rev 1995, 20:140-267.
13. Csernansky J.G., Martin M., Shah R., Bertchume A., Colvin J., Dong H. Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsychopharmacology 2005, 30:2135-2143.
14. Boess F.G., Hendrix M., van der Staay F.J., Erb C., Schreiber R., van Staveren W., et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004, 47:1081-1092.
15. Maître L., Pepeu G. New drugs in memory and learning. Pharmacopsychiatry 1989, 22:S51.
16. Floresco S.B., Jentsch J.D. Pharmacological enhancement of memory and executive functioning in laboratory animals. Neuropsychopharmacology 2010, 36:227-250.
17. Gamzu E.R., Hoover T.M., Gracon S.I., Ninteman M.V. Recent developments in 2-pyrrolidinone-containing nootropics. Drug Dev Res 1989, 18:177-189.
18. Sarter M. Preclinical research into cognition enhancers. Trends Pharmacol Sci 2006, 27:602-608.
19. Sarter M., Hagan J., Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: part I. Psychopharmacology (Berl) 1992, 107:144-159.
20. Cain D.P. Testing the NMDA, long-term potentiation, and cholinergic hypotheses of spatial learning. Neurosci Biobehav Rev 1998, 22:181-195.
21. Olton D.S. Age-related behavioral impairments: benefits of multiple measures of performance. Neurobiol Aging 1993, 14:637-638.
22. van der Staay F.J., Blokland A. Behavioral differences between outbred Wistar, inbred Fischer 344, Brown Norway, and hybrid Fischer 344*Brown Norway rats. Physiol Behav 1996, 60:97-109.
23. D'Hooge R., De Deyn P. Application of the Morris water maze in the study of learning and memory. Brain Res Rev 2001, 36:60-90.
24. Andrews J.S. Possible confounding influence of strain, age and gender on cognitive performance in rats. Brain Res Cogn Brain Res 1996, 3:251-267.
25. Merlini L., Pinza M. Trends in searching for new cognition enhancing drugs. Prog Neuropsychopharmacol Biol Psychiatry 1989, 13:S61-S75.
26. Asin K.E., Fibiger H.C. Spontaneous and delayed spatial alternation following damage to specific neuronal elements within the nucleus medianus raphe. Behav Brain Res 1984, 13:241-250.
27. Gerlai R. A new continuous alternation task in T-maze detects hippocampal dysfunction in mice. A strain comparison and lesion study. Behav Brain Res 1998, 95:91-101.
28. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 1988, 31:47-59.
29. Thor D.H., Holloway W.R. Social memory of the male laboratory rat. J Comp Physiol Psychol 1982, 96:1000-1006.
30. Spowart-Manning L., van der Staay F.J. The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse. Behav Brain Res 2004, 151:37-46.
31. Boess F.G., de Vry J., Erb C., Flessner T., Hendrix M., Luithle J., et al. The novel α7 nicotinic acetylcholine receptor agonist N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy) phenyl]-1-benzofuran-2-carboxamide (ABBF) improves recognition and working memory. J Pharmacol Exp Ther 2007, 321:716-725.
32. de Bruin N., Pouzet B. Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval. Pharmacol Biochem Behav 2006, 85:253-260.
33. Prickaerts J., Si{dotless}k A., Honig W., van der Staay F.J., de Vente J., Blokland A. Dissociable effects of acetylcholinesterase inhibitor and phosphodiesterase type 5 inhibitors on object memory: acquisition versus consolidation. Psychopharmacology 2005, 177:381-390.
34. Dere E., Huston J.P., De Souza Silva M.A. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 2007, 31:673-704.
35. Bouger P.C., van der Staay F.J. Rats with scopolamine- or MK-801-induced spatial discrimination deficits in the cone field task: animal models for impaired spatial orientation performance. Eur Neuropsychopharmacol 2005, 15:331-346.
36. van Kampen M., Selbach K., Schneider R., Schiegel E., Boess F., Schreiber R. AR-R 17779 improves social recognition in rats by activation of nicotinic α7 receptors. Psychopharmacology 2004, 172:375-383.
37. Porsolt R.D., McArthur R.A., Lenègre A. Psychotropic drug screening. Methods in behavioral pharmacology 1993, 23-51. Elsevier, Amsterdam. F. van Haaren (Ed.).
38. Bammer G. Pharmacological investigations of neurotransmitter involvement in passive avoidance responding: a review and some new results. Neurosci Biobehav Rev 1982, 6:247-296.
39. Nilsson M., Hansson S., Carlsson A., Carlsson M.L. Differential effects of the N-methyl-d-aspartate receptor antagonist MK-801 on different stages of object recognition memory in mice. Neuroscience 2007, 149:123-130.
40. de Lima M.N.M., Laranja D.C., Bromberg E., Roesler R., Schröder N. Pre- and post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behav Brain Res 2005, 156:139-143.
41. Mandillo S., Rinaldi A., Oliverio A., Mele A. Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychomimetic drug-induced cognitive deficits. Behav Pharmacol 2003, 14:533-544.
42. Adriani W., Felici A., Sargolini F., Roullet P., Usiello A., Oliverio A., et al. N-methyl-d-aspartate and dopamine receptor involvement in the modulation of locomotor activity and memory processes. Exp Brain Res 1998, 123:52-59.
43. Roullet P., Mele A., Ammassari-Teule M. Involvement of glutamatergic and dopaminergic systems in the reactivity of mice to spatial and non-spatial change. Psychopharmacology 1996, 126:55-61.
44. McLamb R.L., Williams L.R., Nanry K.P., Wilson W.A., Tilson H.A. MK-801 impedes the acquisition of a spatial memory task in rats. Pharmacol Biochem Behav 1990, 37:41-45.
45. Filliat P., Blanchet G. Effects of TCP on spatial memory: comparison with MK-801. Pharmacol Biochem Behav 1995, 51:429-434.
46. Åhlander M., Misane I., Schött P.A., Ögren S.V. A behavioral analysis of the spatial learning deficit induced by the NMDA receptor antagonist MK-801 (dizocilpine) in the rat. Neuropsychopharmacology 1999, 21:414-426.
47. Uekita T., Okaichi H. NMDA antagonist MK-801 does not interfere with the use of spatial representation in a familiar environment. Behav Neurosci 2005, 119:548-556.
48. Vales K., Bubenikova-Valesova V., Klement D., Stuchlik A. Analysis of sensitivity to MK-801 treatment in a novel active allothetic place avoidance task and in the working memory version of the Morris water maze reveals differences between Long-Evans and Wistar rats. Neurosci Res 2006, 55:383-388.
49. Bardgett M.E., Boeckman R., Krochmal D., Fernando H., Ahrens R., Csernansky J.G. NMDA receptor blockade and hippocampal neuronal loss impair fear conditioning and position habit reversal in C57Bl/6 mice. Brain Res Bull 2003, 60:131-142.
50. Caramanos Z., Shapiro M.L. Spatial memory and N-methyl-d-aspartate receptor antagonists APV and MK-801: memory impairments depend on familiarity with the environment, drug dose, and training duration. Behav Neurosci 1994, 108:30-43.
51. Huang Y.-W., Hu W.-W., Chen Z., Zhang L.-S., Sehn H.-Q., Timmerman H., Leurs R., Yanai K. Effect of the histamine H3-antagonist clobenpropit on spatial memory deficits induced by MK-801 as evaluated by radial maze in Sprague-Dawley rats. Behav Brain Res 2004, 151:287-293.
52. Nishiga M., Fujii Y., Sugimoto Y., Konishi M., Kamei C. Effects of NMDA antagonist MK-801 on radial maze performance in Zucker rats. Brain Res 2002, 950:127-129.
53. White A.M., Best P.J. The effects of MK-801 on spatial working memory and within-session spatial learning. Pharmacol Biochem Behav 1998, 59:613-617.
54. Benvenga M.J., Spaulding T.C. Amnesic effect of the novel anticonvulsant MK-801. Pharmacol Biochem Behav 1988, 30:205-207.
55. Castellano C., Cestari V., Ciamei A., Pavone F. MK-801-induced disruptions of one-trial inhibitory avoidance are potentiated by stress and reversed by naltrexone. Neurobiol Learn Mem 1999, 72:215-229.
56. Harrod S.B., Flint R.W., Riccio D.C. MK-801 induced retrieval, but not acquisition, deficits for passive avoidance conditioning. Pharmacol Biochem Behav 2001, 69:585-593.
57. Moreira K.M., Ferreira T.M., Fornari R.V., Figueredo L.Z.P., Oliveira M.G.M. Interaction between M1-muscarinic and glutamatergic NMDA receptors on an inhibitory avoidance task. Brain Res Bull 2005, 67:504-508.
58. Venable N., Kelly P.H. Effects of NMDA receptor antagonists on passive avoidance learning and retrieval in rats and mice. Psychopharmacology 1990, 100:215-221.
59. da Silva A.L., da Silva Martins B., de Mora Linck V., Herrmann A.P., Mai N., Nunes D.S., et al. MK801- and scopolamine-induced amnesias are reversed by an Amazonian herbal locally used as a "brain tonic" Psychopharmacology 2009, 202:165-172.
60. Brosnan-Watters G., Wozniak D.F., Nardi A., Olney J.W. Acute behavioral effects of MK-801 in the mouse. Pharmacol Biochem Behav 1996, 53:701-711.
61. Golden G.J., Houpt T.A. NMDA receptor in conditioned flavor-taste preference learning: blockade by MK-801 and enhancement by d-cycloserine. Pharmacol Biochem Behav 2007, 86:587-596.
62. Hliňák Z., Krejčí I. Spontaneous alternation behaviour in rats: Kynurenic acid attenuates deficits induced by MK-801. Behav Brain Res 2006, 168:144-149.
63. Mackes J.L., Willner J. NMDA antagonist MK-801 impairs acquisition of place strategies, but not their use. Behav Brain Res 2006, 175:112-118.
64. Ogura H., Aigner T.G. MK-801 impairs recognition memory in rhesus monkeys: comparison with cholinergic drugs. J Pharmacol Exp Ther 1993, 266:60-64.
65. Stanhope K.J., McLenachan A.P., Dourish C.I. Dissociation between cognitive and motor/motivational deficits in the delayed matching to position test: effects of scopolamine, 8-OH. DPAT and EAA antagonists. Psychopharmacology 1995, 122.
66. Pitts R.C., Buda D.R., Keith J.R., Cerutti D.T., Galizio M. Chlordiazepoxide and dizocilpine, but not morphine, selectively impair acquisition under a novel repeated acquisition and performance task in rats. Psychopharmacology 2006, 189:135-143.
67. Stuchlík A., Vales K. Systemic administration of MK-801, a non-competitive NMDA-receptor antagonist, elicits a behavioural deficit of rats in the Active Allothetic Place Avoidance (AAPA) task irrespectively of their intact spatial pretraining. Behav Brain Res 2005, 159:163-171.
68. Ko T., Evenden J. The effects of psychotomimetic and putative cognitive-enhancing drugs on the performance of a n-back working memory task in rats. Psychopharmacology 2009, 202:67-78.
69. Andine P., Widermark N., Axelsson R., Nyberg G., Olofsson U., Mårtensson E., et al. Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther 1999, 290:1393-1408.
70. Eyjolfsson E.M., Brenner E., Kondziella D., Sonnewald U. Repeated injection of MK-801: an animal model of schizophrenia?. Neurochem Int 2006, 48:541-546.
71. Tang Y., Zou H., Strong J.A., Cui Y., Xie Q., Jin G.Z., et al. Paradoxical effects of very low dose MK-801. Eur J Pharmacol 2006, 537:77-84.
72. van der Staay F.J., Arndt S.S., Nordquist R.E. Evaluation of animal models of neurobehavioral disorders. Behav Brain Funct 2009, 5(11):23.
73. Noldus L.P.J.J., Spink A.J., Tegelenbosch R.A.J. EthoVision: a versatile video tracking system for automation of behavioral experiments. Behav Res Methods Instrum Comput 2001, 33:398-414.
74. van der Staay F.J., Blokland A. Repeated assessment of spatial discrimination performance of aged rats in the Morris water escape task. Neurobiol Learn Mem 1996, 65:99-102.
75. Cahill L., McGaugh J.L. Amygdaloid complex lesions differentially affect retention of tasks using appetitive and aversive reinforcement. Behav Neurosci 1990, 104:532-543.
76. Lieben C.K., van Oorsouw K., Deutz N.E., Blokland A. Acute tryptophan depletion induced by a gelatin-based mixture impairs object memory but not affective behavior and spatial learning in the rat. Behav Brain Res 2004, 151:53-64.
77. Wilson R.S., Scott K.K. Computer programs for autonomic research. Behav Sci 1970, 15:380-385.
78. Heale V., Harley C. MK-801 and AP5 impair acquisition, but not retention, of the Morris milk maze. Pharmacol Biochem Behav 1990, 36:145-149.
79. Whishaw I.Q., Auer R.N. Immediate and long-lasting effects of MK-801 on motor activity, spatial navigation in a swimming pool and EEG in the rat. Psychopharmacology 1989, 98:500-507.
80. Kant G.J., Wright W.L., Robinson T.N., D'Angelo P. Effects of MK-801 on learning and memory as assessed using a novel water maze. Pharmacol Biochem Behav 1991, 39:479-485.
81. Farber N.B., Wozniak D.F., Price M.T., Labruyere J., Huss J., St.Peter H., et al. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?. Biol Psychiatry 1995, 38.
82. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001, 158:1367-1377.
83. Ohno M., Watanabe S. Interactive processing between glutamatergic and cholinergic systems involved in inhibitory avoidance learning of rats. Eur J Pharmacol 1996, 312:145-147.
84. Smith R.D., Grzelak M.E., Coffin V.L. Reduction of dizocilpine and scopolamine-induced deficits in avoidance responding by SCH 54388, a metabolite of felbamate. Pharmacol Biochem Behav 1997, 58:657-664.
85. Ciamei A., Aversano M., Cestari V., Castellano C. Effects of MK-801 and nicotine combinations on memory consolidation in CD1 mice. Psychopharmacology 2001, 154:126-130.
86. Rocinholi L.F., Almeida S.S., De-Oliveira L.M. Response threshold to aversive stimuli in stimulated early protein-malnourished rats. Braz J Med Biol Res 1997, 30:407-413.
87. Evans W.O. A new technique for the investigation of some analgesic drugs on a reflexive behavior in the rat. Psychopharmacology 1961, 2:318-325.
88. Roesler R., Vianna M.R.M., de Paris F., Quevedo J. Memory-enhancing treatments do not reverse the impairment of inhibitory avoidance retention induced by NMDA receptor blockade. Neurobiol Learn Mem 1999, 72:252-258.
89. Pitsikas N., Zisopoulou S., Sakellaridis N. Nitric oxide donor molsidomine attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801. J Neurosci Res 2006, 84:299-305.
90. King M.V., Sleight A.J., Woolley M.L., Topham I.A., Marsden C.A. F one KCF, 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation-an effect sensitive to NMDA receptor antagonists. Neuropharmacology 2004, 47:195-204.
91. Cestari V., Ciamei A., Castellano C. Strain-dependent effects of MK-801 on passive avoidance behaviour in mice: interactions with morphine and immobilization stress. Psychopharmacology 1999, 146:144-152.
92. van der Staay F.J., Arndt S.S., Nordquist R.E. The standardization-generalization dilemma: a way out. Genes Brain Behav 2010, 9(8):849-855.
93. van der Staay F.J. Assessment of age-associated cognitive deficits in rats: a tricky business. Neurosci Biobehav Rev 2002, 26:753-759.
94. Gamzu E. Animal behavioral models in the discovery of compounds to treat memory dysfunction. Ann NY Acad Sci 1985, 444:370-393.
95. van der Staay F.J., Rutten K., Bärfacker L., DeVry J., Erb C., Heckroth H., et al. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 2008, 55:908-918.
96. Lynch G, Palmer LC, Gall CM. The likelihood of cognitive enhancement. Pharmacol Biochem Behav, in press. doi:10.1016/j.pbb.2010.12.024.
97. Bender C., de Olmos S., Bueno A., de Olmos J., Lorenzo A. Comparative analyses of the neurodegeneration induced by the non-competitive NMDA-receptor-antagonist drug MK801 in mice and rats. Neurotoxicol Teratol 2010, 32:542-550.
98. Gandolfi O., Dall'Olio R., Rimondini R., Borgrani S., Valsecchie B. Repeated administrations of (-)-deprenyl increase [3H]MK801 binding in rat brain and antagonize the impairment of passive avoidance conditioning induced by N-methyl-d-aspartate receptor antagonists. Neurosci Lett 1994, 165:113-116.
99. Jones K.W., Schaeffer C.L., DeNoble V.J. Systematically administered N-methyl-d-aspartate interferes with acquisition of a passive avoidance response in rats. Pharmacol Biochem Behav 1989, 34:185-191.
100. Uchihashi Z., Kuribara H., Isa Z., Morita T., Sato T. The disruptive effect of ketamine on passive avoidance learning in mice. Psychopharmacology 1994, 116:40-44.
101. Lalonde R., Joyal C.C. Effects of ketamine and l-glutamic acid diethyl ester on spatial and nonspatial learning tasks in rats. Pharmacol Biochem Behav 1993, 44:539-545.
102. Alessandri B., Bättig K., Welzl H. Effects of ketamine on tunnel maze and water maze performance in the rat. Behav Neural Biol 1989, 52:194-212.
103. Wesierska M., Macias-Gonzalez R., Bures J. Differential effect of ketamine on the reference and working memory versions of the Morris water maze task. Behav Neurosci 1990, 104:74-83.
104. Aguado L., San Antonio A., Perez L., del Valle R., Gomez J. Effects of the NMDA receptor antagonist ketamine on flavor memory: conditioned aversion, latent inhibition, and habituation of neophobia. Behav Neural Biol 1994, 61:271-281.
105. Traverso L.M., Ruiz G., Camino G., de la Casa L.G. Ketamine blocks the formation of a gustatory memory trace in rats. Pharmacol Biochem Behav 2008, 90:305-311.
106. Dix S., Gilmour G., Potts S., Smith J.W., Tricklebank M. A within-subject cognitive battery in the rat: differential effects of NMDA receptor antagonists. Psychopharmacology 2010, 227-242.
107. Saucier D., Hargreaves E.L., Boon F., Vanderwolf C.H., Cain D.P. Detailed behavioral analysis of water maze acquisition under systemic NMDA or muscarinic antagonism: nonspatial pretraining eliminates learning deficits. Behav Neurosci 1996, 110:103-116.
108. Bertaina-Anglade V., Enjuanes E., Morillon D., Drieu la Rochelle C. The object recognition task in rats and mice: a simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity. J Pharmacol Toxicol Methods 2006, 54:99-105.
109. Wozniak D.F., Olney J.W.,K.L., Price M., Miller J.P. Behavioral effects of MK-801 in the rat. Psychopharmacology 1990, 101:47-56.